Ghent-based Nuclivision, a medtech startup, has raised â¬5M from investors, including LUMO Labs and Heran Partners, to support its AI software platform, Nuclarity. Designed to optimize PET scan processes, Nuclarity enhances diagnostic accuracy while minimizing the need for costly radiotracers, addressing current barriers of radiation exposure and imaging accessibility. Founded in 2022, the company focuses on improving medical imaging in oncology and neurology, aiming to facilitate earlier, safer detection of diseases like cancer and reducing the environmental impact of PET technology.
Nuclivisionâs Nuclarity platform aims to enhance PET imaging by reducing radiotracer dependency, thus improving accessibility and decreasing costs and radiation exposure for patients.
Geoffrey D'hondt emphasizes that Nuclivision's technology not only alleviates time pressures in nuclear medicine but also mitigates health impacts linked to PET scans.
Collection
[
|
...
]